Evidence map›Paper›PMID 37815367›Full record

ArticleInfection and immunity2023

Pedro Miramón, Andrew W Pountain, Michael C Lorenz

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Proteome Remodelling inJournal of fungi (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Review
  6. Diabetes and Immunosuppression Drive Distinct Patterns ofbioRxiv : the preprint server for biology · 2026
    Article
  7. mBio · 2026
    Article
  8. Article
  9. Microbiology spectrum · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. bioRxiv : the preprint server for biology · 2025
    Article
  15. Evolutionary accumulation ofEmerging microbes & infections · 2024
    Article
  16. Article
  17. ThemBio · 2024
    Article
  18. Article
  19. Review
  20. Innate immune response to Candida auris.Current opinion in microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Pedro Miramón *Department of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, USA.ORCID 0000-0002-6867-7697
Andrew W Pountain *NYU Langone Health , New York, New York, USA.ORCID 0000-0001-9651-5145
Michael C LorenzDepartment of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, USA.ORCID 0000-0002-7881-8027
The University of Texas Health Science Center at Houston · USNYU Langone Health · US

Funding

Characterization of novel virulence factors in CandidaR01AI143304 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2019 to 2024
$2.6M
NIAID NIH HHS R01 AI143304
6 · The paper itself

Abstract

The pathogenic yeast

Indexed as

CandidaCandida aurisAntifungal AgentsCandida albicansCandida parapsilosisMacrophagesAntifungal AgentsCandida aurishost-pathogen interactionsmacrophagetranscriptional profile

Identifiers

PMID37815367
PMCPMC10652981
OpenAlexW4387472260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.